Daewoong Bio announced on the 22nd that 'Posidapa,' a generic drug of the diabetes treatment drug Forxiga, has newly added indications for chronic heart failure and kidney disease. With this additional indication, Posidapa has been recognized for all the indications of the original drug Forxiga, whose reimbursement was deleted due to voluntary withdrawal in December last year.
Although generic drugs of Forxiga have been available since 2023, most generic drugs have only been prescribed to patients with type 2 diabetes. With this additional indication, Posidapa can fill the prescription gap as an alternative to Forxiga, whose reimbursement was deleted in December last year.
Recently, the treatment of diabetes patients has increasingly emphasized not only long-term blood sugar control but also complication management. The main ingredient of Posidapa, 'Dapagliflozin,' belongs to the SGLT-2 (sodium glucose cotransporter 2) inhibitor class and has established itself as an essential drug for patients with type 2 diabetes and complications. It is especially recommended for patients with chronic kidney disease, cardiovascular disease, and heart failure.
Guidelines from the American Diabetes Association (ADA) and the Heart Failure Society recommend prioritizing treatments including SGLT-2 inhibitors, which have proven cardiovascular disease reduction effects, for patients with atherosclerotic cardiovascular disease (ASCVD) or heart failure. Additionally, organizations such as the Chronic Kidney Disease Society recommend prioritizing treatments including SGLT-2 inhibitors for diabetic kidney disease patients with albuminuria or reduced glomerular filtration rate (GFR).
Posidapa is a product directly produced through in-house bioequivalence studies based on Daewoong Bio's excellent technology, with the advantage of convenient divided dosing through the insertion of a score line.
Currently, it has been landed in more than 30 tertiary and general hospitals nationwide, including 'Big 5' hospitals such as Seoul Asan Medical Center and Seoul St. Mary's Hospital, as well as Hanyang University Hospital, Pusan National University Hospital, and Jeonbuk National University Hospital.
Daewoong Bio plans to strengthen academic sales and marketing activities in cardiology and nephrology departments by adding indications for chronic heart failure and chronic kidney disease, thereby enhancing its dominance in the SGLT-2 inhibitor market.
Park Jeong-ho, head of the CNE team at Daewoong Bio, said, "With the expansion of indications for Posidapa, we have been able to completely fill the gap left by Forxiga, whose reimbursement was deleted in December last year. Since complication management is very important in type 2 diabetes, we will do our best to ensure that patients can receive smooth treatment based on the expanded indications of Posidapa."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
